Price to book forward of Standard BioTools Inc. – NASDAQ:LAB
This article provides the "Price to book forward" value for Standard BioTools Inc. (NASDAQ: LAB). It indicates that the market was closed at the time of publication, with no trades observed. The data presented is provided by ICE Data Services and FactSet.
Price to earnings forward of Standard BioTools Inc. – BOATS:LAB
The article focuses on the "Price to earnings forward" metric for Standard BioTools Inc. (LAB), as available through the Blue Ocean Alternative Trade System (BOATS:LAB) on TradingView. It appears to list financial data points for this specific metric over various periods, showing value, change, and percentage change.
Enterprise value to revenue forward of Standard BioTools Inc. – NASDAQ:LAB
This article provides financial data for Standard BioTools Inc. (NASDAQ: LAB), specifically its enterprise value to revenue forward. It appears to be a data point or a financial metric provided by TradingView, indicating a key valuation ratio for the company over a future period. The content is primarily a listing of financial data with minimal descriptive text.
Enterprise value to EBITDA forward of Standard BioTools Inc. – NASDAQ:LAB
This article presents the enterprise value to EBITDA forward of Standard BioTools Inc. (NASDAQ:LAB). The information is provided by TradingView, a platform offering financial market data and tools. The article is a snapshot of financial data without further analysis.
Standard BioTools (LAB) director receives new RSU and stock option awards
Standard BioTools (LAB) director Carey Thomas D. received equity compensation comprising 99,116 restricted stock units (RSUs) and stock options for 263,884 shares. The RSUs vest by June 18, 2027, or prior to the next annual stockholders' meeting, while the stock options, with an exercise price of $0.8297 per share, vest in monthly installments starting July 18, 2026. Following these grants, Thomas D. directly holds 344,456 shares of common stock and 263,884 stock options, with vesting contingent on continued service.
Standard BioTools (LAB) awards 500,000 RSUs to chief business officer
Standard BioTools (LAB) has granted 500,000 Restricted Stock Units (RSUs) to its SVP & Chief Business Officer, Sean Mackay. These RSUs, which were provided at no cash cost, will vest in two tranches—40% on June 20, 2027, and 60% on June 20, 2028—contingent on Mackay's continued service to the company. Following this award, Mackay's direct holdings in the company now total 1,506,552 shares.
Form 4 Standard Biotools Inc For: 23 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Standard Biotools Inc. The report, dated for June 23, 2026, was published on June 24, 2026, at 07:52 am, and is accompanied by current market data. The content is brief and serves primarily as an announcement of the filing rather than an in-depth analysis.
Eli Casdin (LAB) granted RSUs and stock options, reports large fund holdings
STANDARD BIOTOOLS director and 10% owner Eli Casdin reported receiving new equity awards, including 99,116 Restricted Stock Units and stock options for 175,923 shares. These awards are part of his compensation and vest over time, contingent on continued service. The filing also detailed Casdin's significant indirect holdings through various investment funds, bringing his total direct and indirect shares to tens of millions.
STANDARD BIOTOOLS (NASDAQ: LAB) director receives new RSU and stock option awards
STANDARD BIOTOOLS (NASDAQ: LAB) director Troy Cox received new RSU and stock option awards as part of his compensation. He was granted 99,116 RSUs vesting by June 18, 2027, and stock options for 175,923 shares with an exercise price of $0.8297, vesting in monthly installments starting July 18, 2026. Following these awards, Cox directly holds 475,702 shares of common stock.
Form 4 Standard Biotools Inc For: 23 June By Investing.com
This article reports on a Form 4 filing for Standard Biotools Inc., dated June 23. While the article title is primarily a headline, it also provides detailed market data including various indices, commodities, bonds, and individual stock performances. It also features trending stocks and several market analysis articles.
STANDARD BIOTOOLS (LAB) director Frank Witney receives new RSU and stock option awards
STANDARD BIOTOOLS INC. director Frank Witney reported receiving new equity awards, consisting of 99,116 Restricted Stock Units (RSUs) and a stock option for 175,923 shares with an exercise price of $0.8297. These awards increase his stake in the company and are subject to vesting schedules tied to continued service. Following these grants, Witney directly holds 309,978 common shares and 4,225 shares indirectly through a revocable trust, in addition to the new stock option position.
STANDARD BIOTOOLS (NASDAQ: LAB) director receives new RSU and stock option awards
STANDARD BIOTOOLS director Kathy L. Hibbs was granted 99,116 Restricted Stock Units and stock options for 175,923 shares on June 18, 2026. These awards increase her direct stake in the company and align her interests with shareholders, with vesting contingent on continued service. The RSUs vest by June 18, 2027, and the stock options, with an exercise price of $0.8297 per share, begin to vest monthly from July 18, 2026.
STANDARD BIOTOOLS (NASDAQ: LAB) director awarded RSUs and stock options in new Form 4
STANDARD BIOTOOLS director Eloi Fenel M was granted 99,116 Restricted Stock Units (RSUs) and stock options for 175,923 shares with an exercise price of $0.8297 per share. The RSUs vest by June 18, 2027, or before the next annual stockholders’ meeting, and the options vest in monthly installments starting July 18, 2026. This compensation aligns with standard director equity awards and increases his long-term equity exposure in the company.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AstroNova, Inc. (Nasdaq – ALOT), Open Lending Corporation (Nasdaq – LPRO), Huntsman Corporation (NYSE – HUN), Standard BioTools Inc. (Nasdaq – LAB)
Brodsky & Smith is investigating potential breaches of fiduciary duties by the Boards of Directors of AstroNova, Inc. (ALOT), Open Lending Corporation (LPRO), Huntsman Corporation (HUN), and Standard BioTools Inc. (LAB) regarding their respective acquisition agreements. The investigations focus on whether the proposed deals offer fair value to shareholders and involved fair processes. Investors are encouraged to contact Brodsky & Smith for discussions without cost or obligation.
Standard BioTools (LAB) investors approve 2026 equity plan and ESPP share increase
Standard BioTools Inc. stockholders approved a new 2026 Equity Incentive Plan and an amendment to the 2017 Employee Stock Purchase Plan, increasing reserved shares by 1,200,000. Additionally, shareholders elected three Class I directors, gave advisory approval for 2025 executive compensation, and ratified PricewaterhouseCoopers LLP as the independent auditor for 2026. The decisions were made at the 2026 Annual Meeting, where 86.04% of voting power was represented.
Standard BioTools Inc (LAB) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides historical data on dividends and stock splits for Standard BioTools Inc (LAB). It notes that no dividend data is available for the past five years and no historical stock split data is provided. The article also includes current stock information for LAB, such as its market capitalization and P/E ratio.
LAB Stock Alert: Halper Sadeh LLC is Investigating Whether Standard BioTools Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Standard BioTools Inc. (NASDAQ: LAB) and Treeline Biosciences, Inc. The investigation focuses on whether Standard BioTools' board failed to secure the best possible price and conduct a fair sales process for shareholders, who are expected to own approximately 16% of the combined company. Shareholders are encouraged to contact Halper Sadeh to discuss their rights and options.
[SCHEDULE 13D/A] STANDARD BIOTOOLS INC. Amended Major Shareholder Report
This SCHEDULE 13D/A filing reports an amended major shareholder report for Standard BioTools Inc. (LAB) by Casdin Capital, LLC and affiliated entities. The filing details their beneficial ownership percentages and outlines a recent merger agreement between Standard BioTools Inc. and Treeline Biosciences, Inc., for which the Casdin entities have entered into a voting and lock-up agreement.
Stealthy startup Treeline plans a reverse merger
Stealthy biotechnology firm Treeline Biosciences, led by former Loxo Oncology CEO Josh Bilenker, is set to go public via a reverse merger with microfluidics company Standard BioTools. Treeline will retain 84.5% ownership of the combined entity, bringing nearly $900 million in cash and a pipeline of cancer drugs, including three in early-stage testing, to the public market. The new company is expected to trade on the Nasdaq under the ticker "TRLN" in the second half of 2026.
Fenwick Represents Treeline Biosciences in Definitive Merger Agreement with Standard BioTools
Fenwick is representing Treeline Biosciences in its definitive merger agreement with Standard BioTools Inc. The combined company will operate as Treeline Biosciences, focusing on advancing its pipeline of small molecule inhibitors, protein degraders, and antibody-drug conjugates. This transaction is expected to add approximately $450 million in net cash from Standard BioTools, resulting in over $900 million in pro-forma cash for the combined entity, sufficient to fund operations into 2029.
Standard BioTools and Treeline Biosciences Announce Merger Agreement
Standard BioTools and Treeline Biosciences have announced a definitive merger agreement in an all-stock transaction, with the combined company set to operate as Treeline Biosciences. The merger is expected to close in the second half of 2026, creating a well-capitalized entity with over $900 million in cash to fund operations into 2029. Treeline Biosciences brings a deep pipeline of clinical-stage programs in oncology, neurology, and immunology, including three Phase 1 programs with anticipated data readouts starting in 2027.
Standard BioTools and Treeline Biosciences Announce $900M Merger to Form Public Biopharma Company Focused on Oncology and Precision Medicines 12
Standard BioTools Inc. (NASDAQ: LAB) and Treeline Biosciences, Inc. have announced an all-stock merger to form a new public biopharma company, Treeline Biosciences (TRLN), focused on oncology and precision medicines. The combined entity is expected to have over $900 million in pro-forma cash, providing an operational runway into 2029, and will be led by Dr. Josh Bilenker, co-founder and CEO of Treeline. Standard BioTools shareholders will receive contingent value rights for potential future payouts from legacy asset monetization and earnouts from the SomaLogic business sale, with the merger anticipated to close in the second half of 2026.
Standard BioTools and Treeline Biosciences Agree to Merger, Creating Well-Funded Clinical-Stage Biopharma Company
Standard BioTools Inc. (NASDAQ: LAB) is merging with Treeline Biosciences in an all-stock transaction, transforming Standard BioTools into a clinical-stage biotechnology company focused on precision medicines for cancer and other serious diseases. The combined entity, which will operate as Treeline Biosciences (TRLN) and trade on Nasdaq, is expected to launch with over $900 million in pro forma cash, funding operations into 2029. Treeline Biosciences, founded in 2021, has rapidly advanced several oncology programs into clinical development, including lead candidates targeting BCL6, pan-KRAS, and EZH2, with leadership largely remaining with Treeline's experienced team.
Standard BioTools to Merge With Treeline in All-Stock Deal Valuing Treeline at $2.5 Billion
Standard BioTools (LAB) has agreed to an all-stock merger with Treeline Biosciences, valuing Treeline at $2.5 billion and Standard BioTools at $460 million, adjusted for net cash. Post-merger, former Treeline holders will own approximately 84% of the combined entity, which will be renamed Treeline Biosciences Holdings. The deal also includes voting commitments from major holders, lock-up agreements for insiders, and a five-year Contingent Value Rights (CVR) agreement to distribute proceeds from legacy asset monetization to existing Standard BioTools stockholders.
Standard BioTools and Treeline Biosciences Announce Merger Agreement
Standard BioTools Inc. and Treeline Biosciences, Inc. have announced a definitive merger agreement in an all-stock transaction. The combined company, to be named Treeline Biosciences, will focus on advancing a pipeline of small molecule inhibitors, protein degraders, and targeted therapy antibody-drug conjugates, with over $900 million in cash expected at closing. Treeline's CEO, Josh Bilenker, MD, will lead the new entity, which anticipates clinical data readouts starting in 2027 and plans for additional programs to enter the clinic in oncology, neurology, and immunology.
Clinical-stage cancer biotech Treeline sees path to public markets via reverse merger
Treeline Biosciences, a well-funded cancer company, plans to go public by merging with omics outfit Standard BioTools, with the combined entity retaining the Treeline name and Nasdaq ticker TRLN. The deal, expected to close in the second half of 2026, aims to leave Treeline with $900 million in cash, lasting into 2029, and will retain Treeline's CEO, Josh Bilenker. Treeline's pipeline includes three phase 1 clinical assets for cancer and a fourth program set to enter the clinic, along with future plans to expand into neurology and immunology.
Standard BioTools Regains Compliance With Nasdaq's Minimum Bid Price Requirement
Standard BioTools, Inc. (NASDAQ: LAB) has announced it has regained compliance with Nasdaq's minimum bid price requirement. The company received a letter from Nasdaq confirming its closing bid price was at $1.00 per share or greater for ten consecutive business days, resolving the prior non-compliance notification.
Standard BioTools Inc. 8-K Filing Details for June 5, 2026: Company Information, NASDAQ Listing, and Legal Disclosures
Standard BioTools Inc. (NASDAQ: LAB) has regained compliance with Nasdaq's minimum bid price requirement, as confirmed by a June 5, 2026 letter from the Nasdaq Listing Qualifications Department. This resolution alleviates previous non-compliance issues from an April 20, 2026 notice, removing the threat of delisting and positively impacting the company's market access and investor confidence. The 8-K filing contains details on the company's entity, NASDAQ listing, and investor considerations.
Standard BioTools (NASDAQ: LAB) back in compliance with Nasdaq bid rule
Standard BioTools Inc. (NASDAQ: LAB) has regained compliance with Nasdaq's minimum bid price rule, as confirmed by Nasdaq on June 5, 2026. This resolves a prior notice from April 20, 2026, when the company's stock fell below $1.00 per share for 30 consecutive business days. Maintaining compliance ensures the company's continued listing on the Nasdaq Global Select Market.
Standard BioTools regains Nasdaq bid-price compliance; matter closed
Standard BioTools (LAB) has regained compliance with Nasdaq's $1.00 bid-price rule, officially closing the deficiency matter. The company received notification from Nasdaq on June 5, 2026, confirming its compliance after being previously flagged on April 20, 2026, when its closing bid fell below $1.00 for 30 consecutive business days. This resolution was reported in an SEC Filing (8-K) on June 5, 2026.
Standard BioTools (LAB) awards 500,000 RSUs to Chief Business Officer
Standard BioTools Inc. has granted 500,000 restricted stock units (RSUs) to its Chief Business Officer, Sean Mackay, under its 2026 Equity Incentive Plan. This award, effective June 20, 2026, will vest in two tranches: 40% on June 20, 2027, and the remaining 60% on June 20, 2028, contingent on his continued service. The grant is also subject to the company's 2026 Change of Control and Severance Plan.
Standard BioTools CFO Alex Kim and CBO Sean Mackay enter 2026 Severance Plan; CEO Michael Egholm joins 2023 Plan
Standard BioTools announced that CFO Alex Kim and CBO Sean Mackay have entered into participation agreements under the company's 2026 Change of Control and Severance Plan, effective May 27, 2026. Additionally, CEO Michael Egholm entered a participation agreement under the company's 2023 Change of Control and Severance Plan, effective May 22, 2026. This information was confirmed following an SEC filing by the company.
Standard BioTools - approves 2026 change of control and severance plan on May 21, 2026
Standard BioTools Inc. approved its 2026 change of control and severance plan on May 21, 2026. This news was reported on May 28, 2026, by Reuters. The article also provides recent news headlines related to the company's earnings reports, equity buyback plan, and the completion of its SomaLogic sale to Illumina.
Standard BioTools (LAB) sets new executive and CEO change-of-control severance terms
Standard BioTools Inc. (LAB) has approved new and updated executive severance plans for its leadership team and an amended plan for its CEO, Michael Egholm, Ph.D. These plans outline cash, equity, and benefit protections for qualifying terminations and change of control events, with initial terms extending through August 4, 2028. CFO Alex Kim and Chief Business Officer Sean MacKay have entered participation agreements under the new 2026 plan, which supersedes previous arrangements for these executives. The plans detail different severance benefits based on whether the termination occurs within or outside a defined change of control period.
Standard Biotools (LAB) SVP has 25,729 shares withheld for taxes
Standard Biotools (LAB) SVP and Chief Business Officer, Sean Mackay, had 25,729 shares of common stock withheld on May 20, 2026, to satisfy tax obligations related to vested restricted stock units. This transaction is a routine tax-withholding event and not an open-market sale or purchase. Following this, Mackay directly holds 1,006,552 shares of common stock.
STANDARD BIOTOOLS (LAB) CFO has 18,871 shares withheld for RSU taxes
STANDARD BIOTOOLS INC. CFO Hanjoon Alex Kim reported a routine tax-related share disposition. On May 20, 2026, 18,871 common shares were withheld to cover tax obligations arising from vesting restricted stock units. After this transaction, Kim directly holds 2,760,530 shares, and the filing clarifies this was a tax withholding, not an open-market sale.
STANDARD BIOTOOLS (LAB) CEO has shares withheld to cover RSU tax obligations
STANDARD BIOTOOLS INC.'s President & CEO, Michael Egholm, had 97,626 shares of common stock withheld on May 20, 2026, to cover tax obligations arising from the vesting of previously granted restricted stock units. This was a tax- and compensation-driven event, not an open-market trade, and Egholm now directly holds 6,597,956 shares. The shares were withheld at a value of $1.00 per share.
DKSH : and Standard BioTools Announce Distribution Partnership to Expand Spatial Biology and Proteomics Solutions in Australia and New Zealand
DKSH and Standard BioTools have announced a distribution partnership to expand the reach of spatial biology and proteomics solutions in Australia and New Zealand. DKSH will provide sales, distribution, application, and after-sales support for Standard BioTools' product portfolio, leveraging its local presence and expertise. This collaboration aims to offer integrated workflow solutions and enhanced support for researchers in the region, fostering innovation in life sciences.
SomaLogic stock (US82489T1043): merger with Standard BioTools reshapes proteomics player
SomaLogic has completed an all-stock merger with Standard BioTools, creating a new life-science tools group focused on proteomics and genomics. This strategic move aims to diversify their offerings, enhance scale, and reduce costs. The combined entity seeks to leverage its expanded platform to drive growth in the multi-omics market while navigating integration challenges and competitive pressures.
SomaLogic Inc stock (US82489T1043): Illumina merger closes and reshapes proteomics story
SomaLogic Inc has completed its all-stock merger with Standard BioTools, forming a combined life-science tools company focused on proteomics and multi-omics. This strategic move aims to accelerate advanced proteomics adoption, create cost synergies, and broaden their product portfolio for academic research, biopharma, and diagnostics development. The new entity will operate under the Standard BioTools name, with former SomaLogic shareholders holding a significant minority stake.
MAK Capital (NASDAQ: LAB) reports 6.7% stake in Standard BioTools
MAK Capital and related entities have reported a 6.7% passive stake in Standard BioTools Inc. (NASDAQ: LAB) through a Schedule 13G/A SEC filing. This ownership amounts to 26,172,626 shares, with shared voting and dispositive power, calculated as of May 15, 2026, against 390,368,119 shares outstanding. The filing indicates a neutral impact and sentiment, with no immediate transactional activity or board engagement disclosed.
Viking Global (LAB) holds 58.65M shares (~15%) of Standard BioTools
Viking Global Investors and its affiliated entities have reported a beneficial ownership of 58.65 million shares, representing a 15.0% stake in Standard BioTools (LAB). This disclosure was made via an amended Schedule 13G/A filing with the SEC, specifying the holdings are split between Viking Global Opportunities (VGOP) and Viking Global Opportunities Drawdown (VGOD). The filing also noted the removal of David C. Ott as a reporting person due to his retirement.
Standard Biotools Faces Nasdaq Delisting Risk After Prolonged Sub-$1 Share Price
Standard Biotools Inc. (LAB) is at risk of delisting from Nasdaq because its share price has traded below the $1.00 minimum bid for 30 consecutive business days. The company received a deficiency notice on April 20, 2026, and must regain compliance by October 19, 2026, to avoid potential delisting. Delisting could negatively impact share liquidity and the company's ability to raise capital.
Number of shareholders of Standard BioTools Inc. – NASDAQ:LAB
This article provides the number of shareholders for Standard BioTools Inc. (NASDAQ: LAB). It indicates that the market is currently closed with no trades. The data is presented within the context of TradingView's platform, highlighting its financial and market analysis features.
Standard BioTools (LAB) Premium P/S Multiple Tests Narratives After Another Quarterly Loss
Standard BioTools (LAB) reported Q1 2026 revenue of US$21.1 million and an EPS loss of US$0.04, continuing a trend of quarterly losses. The company's trailing 12-month revenue growth was a modest 0.9%, below market benchmarks, and it maintains a premium Price/Sales (P/S) multiple of 4.4x despite ongoing unprofitability. This performance raises questions about its valuation and ability to achieve profitability and significant revenue growth as predicted by some narratives.
Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry
Molecular Instruments (MI) and Standard BioTools Inc. have announced a collaboration to integrate MI's HCR™ signal amplification technology with Standard BioTools' Imaging Mass Cytometry™ (IMC™). This partnership aims to significantly enhance multi-omic spatial analysis by enabling high-sensitivity, high-plex detection of a wide array of biomarkers, including RNA and protein, at subcellular resolution. The collaboration will initially focus on developing and validating HCR-amplified multi-omic workflows for the Hyperion™ Imaging System and will include joint marketing and sales efforts.
Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry
Molecular Instruments (MI) and Standard BioTools Inc. (Nasdaq: LAB) have announced a collaboration to combine MI's programmable in situ amplification technology with Standard BioTools' Imaging Mass Cytometry platform. This partnership aims to enable highly multiplexed, ultra-sensitive, and quantitative spatial analysis of RNA and protein in biological samples. The integration is expected to offer researchers unprecedented insights into cellular function and tissue microenvironments.
Standard BioTools 1Q Loss/Shr 4c >LAB
Standard BioTools announced a first-quarter loss per share of 4 cents. This financial update indicates the company's performance for the most recent quarter.
Standard BioTools Reports First Quarter 2026 Financial Results
Standard BioTools Inc. (NASDAQ: LAB) reported strong first-quarter 2026 financial results, with revenue reaching $21.1 million, a 5% increase year-over-year. The company significantly reduced its operating loss by 54% and improved adjusted EBITDA by 78%, putting it on track for positive adjusted EBITDA by the end of 2026. With $524 million in cash and investments, the company plans to pursue an inorganic growth strategy and strategic capital deployment following the sale of SomaLogic to Illumina.
Standard BioTools: Q1 Earnings Snapshot
Standard BioTools Inc. (LAB) announced its Q1 earnings, reporting a net income of $127.1 million. The company posted a profit of 33 cents per share and adjusted losses of 2 cents per share, with revenue for the period reaching $21.1 million.
